MNKD logo

MANNKIND CORP

MNKDNASDAQ
πŸ† #2165 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track MNKD
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.24B
Small Cap
πŸ“ˆRevenue Growth (YoY)
30.5%
High Growth
πŸ“ŠGross Margin
76.8%
High
πŸ’΅FCF Margin
12.7%
Healthy
βš–οΈP/S Ratio
3.2x
Fair
Otter Score
84
Strong
No chart data available for MNKD.

Trading Snapshot

Day Range
β€”
52-Week Range
$2.23 – $6.51
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
321.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$349M
Last Q Revenue
$102M
P/E Ratio
β€”
P/S Ratio
3.2x
EPS (TTM)
$-0.14
Dividend Yield
β€”
Dilution (1yr)
+8.1%
MNKD logo

MANNKIND CORP

MNKD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$349Mβ–² +22.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
82.5%β–² +12.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$39Mβ–Ό βˆ’46.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$14Mβ–Ό βˆ’58.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
314.1Mβ–² +8.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$399Mβ–Ό βˆ’$288M YoY
StockOtter Β· stockotter.space

About MANNKIND CORP

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100
Analyst data unavailable.

Latest News & Updates

News unavailable.